Female sexual dysfunction in postmenopausal women: Systematic review of placebo-controlled trials

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 1, 2003, Pages 286-293

  Modelska, Katharina ^a   Cummings, Steven ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Female sexual dysfunction; Hormone replacement therapy; Postmenopausal women; Sildenafil citrate; Tibolone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANDROGEN; ARGININE; CLONIDINE; CONJUGATED ESTROGEN; CYCLIC GMP; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; PHENTOLAMINE; PROGESTERONE; SILDENAFIL; TIBOLONE;

ACNE; AGITATION; CLINICAL TRIAL; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HIRSUTISM; HORMONAL THERAPY; HUMAN; LIBIDO; MENOPAUSAL SYNDROME; META ANALYSIS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037252621     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.117     Document Type: Review

References (87)

1. Laumann E, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
2. Berman JB, Berman LA, Werbin TJ, Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 1999;9:563-8.
3. Michelson DB, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000;157:229-43.
4. Spector IC, Carey MP. Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 1990;19:389-408.
5. Basson RB, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888-93.
6. Berman JA, Adhikari SP, Goldstein I. Anatomy and physiology of female sexual function and dysfunction: classification, evaluation and treatment options. Eur Urol 2000;38:20-9.
7. Rosen RL, Laumann EO, Paik A. Sexual dysfunction in the United States. JAMA 1999;282:1229.
8. Goldstein, Berman J. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 1998;10(Suppl):S84-90, S98-101.
9. Duncan LL, Lewis C, Jenkins P, Pearson TA. Does hypertension and its pharmacotherapy affect the quality of sexual function in wonten? Am J Hypertens 2000;13:640-7.
10. Grimm RJG, Grandits GA, Prineas RJ, McDonald RFI, Lewis CE, Flack JM, Yunis C, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997;29:8-14.
11. Romeo JS, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000;163:788-91.
12. Gilon D. Sexual activity and coronary artery disease: multiple options. Am J Cardiol 1995;76:1321-2.
13. Drory YF, Fishman EZ, Shapira Y, Pines A. Ventricular arrhythmias during sexual activity in patients with coronary artery disease. Chest 1996;109:922-4.
14. Fabra MP, Porst H. Bulbocavernosus-reflex latencles and pudendal nerve SSEP compared to penile vascular testing in 669 patients with erectile failure and other sexual dysfunction. Int J Impot Res 1999;11:167-75.
15. Hayward WF, Fritz KR, Greene ER. Human middle cerebral artery blood velocity during sexual intercourse. J Ultrasound Med 2000;19:871-6.
16. Lai AG, Goodwin SC, Bonilla SM, Lai AP, Yegul T, Vott S, DeLeon M. Sexual dysfunction after uterine artery embolization. J Vasc Intervent Radiol 2000;11:755-8.
17. Victor B. Depression, antidepressants, and sexual function. Focus 1995;10:5-6.
18. Weiss EL, Longhurst JG, Mazure CM. Childhood sexual abuse as a risk factor for depression in women: psychosocial and neurobiological correlates. Am J Psychiatry 1999;156:816-28.
19. Clayton A. Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 2001;62:5-9.
20. Malavaud BM, Mouzin M, Tricoire JL, Gamé X, Rischmann P, Sarramon JP, Puget J. Evaluation of male sexual function after pelvic trauma by the International Index of Erectile Function. Urology 2000;55:842-6.
21. Copeland CB, Bosse MJ, McCarthy ML, MacKenzie EJ, Guzinski GM, Hash CS, Burgess AR. Effect of trauma and pelvic fracture on female genitourinary, sexual, and reproductive function. J Orthopaed Trauma 1997;11:73-81.
22. Gurvits TG, Gilbertson MW, Lasko NB, Orr SP, Pitman RK. Neurological status of combat veterans and adult survivors of sexual abuse PTSD. Ann N Y Acad Sci 1997;821:468-71.
23. Riley AR, Riley E. Controlled studies on women presenting with sexual drive disorder, I: endocrine status. J Sex Marital Ther 2000;26:269-83.
24. Bancroft J. Cardiovascular and endocrine changes during sexual arousal and orgasm. Psychosom Med 1999;61:290-1.
25. Goggin KE, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med 1998;60:11-6.
26. Sipski M, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55:812-5.
27. Sipski MA, Alexander CJ, Rosen R. Sexual arousal and orgasm in women: effects of spinal cord injury. Ann Neurol 2001;49:35-44.
28. Harrison JG, Glass CA, Owens RG, Soni BM. Factors associated with sexual functioning in women following spinal cord injury. Paraplegia 1995;32:687-92.
29. Hulter BL, Lundberg PO. Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:83-6.
30. Champion JS, Shain RN, Piper J, Perdue ST. Sexual abuse and sexual risk behaviors of minority women with sexually transmitted diseases. West J Nurs Res 2001;23:241-54.
31. Greendale GP, Peterson L, Zibecchi L, Ganz PA. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 2001;8:111-9.
32. Ganz PD, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371-80.
33. Shepherd JP, Peersman G, Weston R, Napuli I. Cervical cancer and sexual lifestyle: a systematic review of health education interventions targeted at women. Health Educ Res 2000;15:681-94.
34. Ganz PR, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.
35. Lamb MS, Sheldon TA. The sexual adaptation of women treated for endometrial cancer. Cancer Pract 1994;2:103-13.
36. Flay LM, Matthews JH. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. Int J Radiat Oncol Biol Physics 1995;31:399-404.
37. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
38. Sadovsky R, Miller TM, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001; 55:75-6.
39. Lewis RB, Bennett CJ, Borkon WD, Boykin WH, Althof SE, Stecher VJ, Siegel RL. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 2001;57:960-5.
40. Boyce E, Umland E. Sildenafil citrate: a therapeutic update. Clin Ther 2001;23:2-23.
41. Turko IB, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 1999;56:124-30.
42. Steers W. Viagra - after one year. Urology 1999;54:12-7.
43. Goldstein IL, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
44. Walker DA, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29:297-310.
45. Guay A, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-7.
46. Palumbo F, Bettocchi C, Selvaggi FP, Pryor JP, Ralph DJ. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001;40:176-80.
47. Hussain I, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ, Krüger THC, Koch M, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4.
48. Prieto Castro R, Anglada Curado FJ, Requiero Lopez JC, Leva Vallejo ME, Molina Sanchez J, Saceda Lopez JL, Requena Tapia MJ. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. Br J Urol Int 2001;88:241-3.
49. Basson R, McInnes R, Smith MD, Hodgson G, Spain T, Koppiker N. Efficacy and safety of sildenafil in estrogenized women with sexual dysfunction associated with female sexual arousal disorder. Obstet Gynecol 2000;95:S1-54.
50. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-43.
51. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogenonly therapy: sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-56.
52. Caruso S, Intelisano GL, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynaecol 2001;108:623-8.
53. Kaplan SR, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE, Martins AC. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-6.
54. Nurnberg HH, Hensley PL, Lauriello J, Parker LM, Keith SJ. Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Serv 1999;50:1076-8.
55. Shen WW, Vrosevich Z, Clayton DO. Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. J Reprod Med 1999;44:535-42.
56. Fava MR, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67:328-31.
57. Utian WH. The true clinical features of postmenopause and oophorectomy, and their response to oestrogen therapy. S Afr Med J 1972;46:732-7.
58. Coope J. The effect of "natural" oestrogen replacement therapy on menopausal symptoms. Postgrad Med J 1976;52:27.
59. Miller M, Franklin K. Theoretical basis for the benefit of postmenopausal estrogen substitution. Exp Gerontol 1999;34:587-604.
60. Hilditch J, Lewis J, Ross A, Peter A, van Maris B, Franssen E. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996;24:177-84.
61. Slater C, Sourer I, Zhang C, Guan C, Stanczyk F, Mishell D. Pharmacokinetics of testosterone after percutaneous gel or buccal administration. Fertil Steril 2001;1:32-7.
62. Davis S, Burger H. Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996;81:2759-63.
63. Sarrel P. Psychosexual effects of menopause: role of androgens. Am J Obstet Gynecol 1999;180:319-24.
64. Basson R. Androgen replacement for women. Can Faro Physician 1999;45:2100-7.
65. Sherwin B. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998;43:98-103.
66. Studd J, Collins WP, Chakravarti S. Oestradiol and testosterone implants in the treatment of psychosexual problems in postmenapausal women. BrJ Obstet Gynaecol 1977;84:314-5.
67. Sherwin B, Gelfand M. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409.
68. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
69. Rosenberg MJ, King TD, Timmons MC. Estrogen-androgen for hormone replacement: a review. J Reprod Med 1997;42:394-404.
70. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. Steroid Biochem Mol Biol 2001;76:231-8.
71. Tang B, Markiewicz LK, Kloosterboer HJ, Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 1993;45:345-51.
72. Markiewicz L, Gurpide E. Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells. J Steroid Biochem Mol Biol 1994;48:89-94.
73. Nevinny-Stickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch Gynecol 1983;234:27-31.
74. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28-41.
75. Nathorst-Böös J, Hammar M. Effect on sexual life - a comparison between fibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997:15-20.
76. Dören M, Ruebig A, Coelingh Bennik HJT, Holzgreve W. Differential effects on the androgen, status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-8.
77. Wu M-H, Pan S-T W, Hsu C-C, Chang F-M, Huang K-E. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314-9.
78. Murray W. Decreased libido in postmenopausal women. Nurse Pract Forum 2000;11:219-24.
79. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384-92.
80. Jubelirer SC, Crowell EB Jr. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia. W Va Med J 2000;96:602-4.
81. Strickler R, Stovall D, Merritt D, Shen W, Wong M, Silfen S. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000;96:359-65.
82. Pritchard K. Endocrine therapy for breast cancer. Oncology 2000;14:493, 497-8.
83. Chen J, Wollman Y, Chernichovsky T, Iaina A, Fofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. Br J Urol Int 1999;83:269-73.
84. Klotz T, Mathers MB, Braun M, Bloch W, Engelmann U. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999;63:220-3.
85. Meston CG, Gorzacka BB, Wright JM. Inhibition of subjective and physiological sexual arousal in women by clonidine. Psychosore Med 1997;59:399-407.
86. Boyarsky BH, Haque W, Rouleau MR, Hirschfeld RM. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999;9:175-9.
87. Derouet HW, Welrauch A, Bewermeier H. Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction. Urologe 1996;35:62-7.